SCHEMBL21731189

SCHEMBL21731189

Cc1cc(-c2c(-c3cccc(F)c3)nc(N)n3ncnc23)cc(C(F)(F)F)n1

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 18/20 0.68
▸ ADORA2B P29275 8/20 0.68
▸ ADORA1 P30542 7/20 0.50
▸ EGLN2 Q96KS0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21731240 0.90 ADORA2A (0.54) ADORA2AADORA2BADORA1
SCHEMBL21731042 0.90 ADORA2A (0.69) ADORA2AADORA2BADORA1
SCHEMBL21731020 0.89 ADORA2A (0.67) ADORA2AADORA2BADORA1
SCHEMBL21731134 0.85 ADORA2A (0.69) ADORA2AADORA2BADORA1
SCHEMBL21731017 0.85 ADORA2A (0.58) ADORA2AADORA2BADORA1
SCHEMBL21731242 0.85 ADORA2A (0.57) ADORA2AADORA2BADORA1
SCHEMBL21731019 0.85 ADORA2A (0.59) ADORA2AADORA2BADORA1
SCHEMBL21731130 0.84 ADORA2A (0.58) ADORA2AADORA2BADORA1
SCHEMBL21731015 0.84 ADORA2A (0.67) ADORA2AADORA2BADORA1
SCHEMBL21731014 0.84 ADORA2A (0.56) ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3611174-B1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR MEDSHINE DISCOVERY INC (CN) 2022-06-08 — — EP disclosed
US-11117899-B2 [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor MEDSHINE DISCOVERY INC. (CN) 2021-09-14 — — US disclosed
US-11066411-B2 — — 2021-07-20 — — US disclosed
US-20200131184-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2020-04-30 — — US disclosed
EP-3611174-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR Medshine Discovery Inc. (CN) 2020-02-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117899-B2 [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885
US-11066411-B2 — ADORA2A, ADORA1, ADORA2B ADORA2A 1/4885ADORA2B 3/4885ADORA1 2/4885
US-20200131184-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback